- Home
- CALC vs ABVC Comparison
CALC vs ABVC Comparison
Compare CALC & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- ABVC
- Stock Information
- Founded
- CALC 2011
- ABVC 2015
- Country
- CALC United States
- ABVC United States
- Employees
- CALC N/A
- ABVC N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- CALC Health Care
- ABVC Health Care
- Exchange
- CALC Nasdaq
- ABVC Nasdaq
- Market Cap
- CALC 48.1M
- ABVC 52.1M
- IPO Year
- CALC N/A
- ABVC N/A
- Fundamental
- Price
- CALC $2.91
- ABVC $3.30
- Analyst Decision
- CALC Strong Buy
- ABVC
- Analyst Count
- CALC 2
- ABVC 0
- Target Price
- CALC $14.50
- ABVC N/A
- AVG Volume (30 Days)
- CALC 91.2K
- ABVC 223.6K
- Earning Date
- CALC 08-12-2025
- ABVC 08-13-2025
- Dividend Yield
- CALC N/A
- ABVC N/A
- EPS Growth
- CALC N/A
- ABVC N/A
- EPS
- CALC N/A
- ABVC N/A
- Revenue
- CALC N/A
- ABVC $391,242.00
- Revenue This Year
- CALC N/A
- ABVC $735.18
- Revenue Next Year
- CALC N/A
- ABVC N/A
- P/E Ratio
- CALC N/A
- ABVC N/A
- Revenue Growth
- CALC N/A
- ABVC 186.84
- 52 Week Low
- CALC $1.42
- ABVC $0.40
- 52 Week High
- CALC $5.97
- ABVC $5.48
- Technical
- Relative Strength Index (RSI)
- CALC 52.85
- ABVC 56.53
- Support Level
- CALC $2.31
- ABVC $2.90
- Resistance Level
- CALC $3.00
- ABVC $3.06
- Average True Range (ATR)
- CALC 0.34
- ABVC 0.28
- MACD
- CALC -0.12
- ABVC 0.00
- Stochastic Oscillator
- CALC 40.00
- ABVC 91.92
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.